11/23/21 16:53 | 11/22/21 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | P | 113 | 2.26 | 0 | 50 | 999% | 51 | D | | | | | | | | | | | | | | |
4/5/17 16:15 | 4/4/17 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S | -1 | 2.41 | 0 | 0 | -2 | 18 | D | -61 | -31 | -13 | -10 | -6 | -2 | -8 | -4 | 4 | 0 | 5 | | | |
3/1/17 17:11 | 2/28/17 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S.d | -1 | 2.61 | 0 | 0 | -3 | 18 | D | -48 | -26 | -11 | 6 | -4 | -2 | 2 | 0 | 0 | -6 | 2 | | | |
9/21/16 16:07 | 9/20/16 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S | -3 | 2.89 | 0 | -1 | -6 | 18 | D | -68 | -53 | -22 | -2 | -5 | 3 | -2 | -2 | 2 | 0 | -13 | -19 | -15 | |
4/6/16 17:01 | 4/5/16 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S | -1 | 3.52 | 0 | 0 | -2 | 20 | D | -73 | -44 | -33 | -24 | -3 | -4 | -2 | 2 | 0 | -2 | 15 | -14 | -22 | -32 |
3/2/16 16:31 | 3/1/16 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S | -2 | 3.51 | 0 | 0 | -2 | 20 | D | -73 | -31 | -43 | -42 | -9 | 1 | -9 | -2 | -2 | 4 | -5 | -9 | -19 | -32 |
9/21/15 16:57 | 9/18/15 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | S.VP,GC | S | -7 | 6.32 | 0 | -1 | -5 | 20 | D | -36 | -31 | 9 | -3 | -11 | 3 | -6 | -3 | 2 | -14 | -16 | -22 | -40 | -53 |
7/7/10 16:16 | 7/2/10 | ABIO | Arca Biopharma, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Ozeroff Christopher David | CO | O | SVP,GC | M.d | 0 | 0.0600 | 0 | 4 | 11 | 42 | D | -71 | 22 | 1 | -35 | -21 | -21 | -13 | -3 | 5 | 17 | 24 | 17 | -1 | -49 |